49 results on '"Eviatar, T."'
Search Results
2. POS1198 EPIDEMIOLOGY OF VEXAS SYNDROME IN ISRAEL – A HIGH PREVALENCE OF UBA1 p.M41V PATHOGENIC VARIANT IN ISRAELI VEXAS PATIENTS
- Author
-
Eviatar, T., primary, Zisapel, M., additional, Feinstein Goren, N., additional, Sagy, I., additional, Kivity, S., additional, Lidar, M., additional, Bieber, A., additional, Tayer-Shifman, O., additional, Peleg, H., additional, Ozeri, D., additional, Shamash, J., additional, Pras, E., additional, Baris-Feldman, H., additional, Edel, Y., additional, Dortort Lazar, A., additional, Wolach, O., additional, Molad, Y., additional, Stremer, G., additional, Naffa, M. E., additional, Porges, T., additional, and Elkayam, O., additional
- Published
- 2024
- Full Text
- View/download PDF
3. AB0981 REAL-WORLD TREATMENT PATTERNS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS - INCREASED PRESCRIPTION OF HYDROXYCHLOROQUINE DOES NOT INCREASE ITS UPTAKE, WHILE REDUCED PRESCRIPTION OF CORTICOSTEROIDS RESULTS IN REDUCED DAMAGE ACCRUAL
- Author
-
Eviatar, T., primary, Yahalom-Golan, R., additional, Livnat, I., additional, Elboim, M., additional, Chodick, G., additional, Rosenberg, V., additional, and Paran, D., additional
- Published
- 2024
- Full Text
- View/download PDF
4. POS1388 SEMEN ANALYSIS OF PATIENTS WITH PSORIATIC ARTHRITIS, AXIAL SPONDYLOARTHRITIS AND HEALTHY CONTROLS
- Author
-
Meridor, K., primary, Barda, S., additional, Elalouf, O., additional, Furer, V., additional, Pel, S., additional, Nochomovitz, H., additional, Zisapel, M., additional, Wollman, J., additional, Tzemach, R., additional, Berman, M., additional, Borok, S., additional, Sarbagil-Maman, H., additional, Padova, H., additional, Levartovsky, D., additional, Broyde, A., additional, Berman, J., additional, Eviatar, T., additional, Ofir-Dovrat, T., additional, Shochat, T., additional, Paran, D., additional, Hauser, R., additional, Elkayam, O., additional, and Polachek, A., additional
- Published
- 2024
- Full Text
- View/download PDF
5. AB0809 INTERSTITIAL LUNG DISEASE SECONDARY TO ANTI SYNTHETASE SYNDROME AND SYSTEMIC SCLEROSIS: DIFFERENCES IN CHARACTERISTICS AND IMMUNOSUPPRESSIVE TREATMENT RESPONSE
- Author
-
Eviatar, T., primary, Freund, O., additional, Shalmon, T., additional, Schneer, S., additional, Adir, Y., additional, Wand, O., additional, Shitrit, D., additional, Elkayam, O., additional, Bar-Shai, A., additional, and Unterman, A., additional
- Published
- 2023
- Full Text
- View/download PDF
6. AB1293 OMICRON BREAKTHROUGH INFECTIONS AMONG RITUXIMAB AND NON-RITUXIMAB TREATED PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES: A MULTICENTER CONTROLLED STUDY
- Author
-
Furer, V., primary, Eviatar, T., additional, Zisman, D., additional, Peleg, H., additional, Paran, D., additional, Levartovsky, D., additional, Kaufman, I., additional, Broyde, A., additional, Polachek, A., additional, Feld, J., additional, Haddad, A., additional, Gazitt, T., additional, Elias, M., additional, Hijaze, N., additional, Friedlander, Y., additional, and Elkayam, O., additional
- Published
- 2023
- Full Text
- View/download PDF
7. AB0602 SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN ISRAEL: GENDER DIFFERENCES IN MANIFESTATIONS, MANAGEMENT AND COMORBIDITIES
- Author
-
Eviatar, T., primary, Rosenberg, V., additional, Elkayam, O., additional, Chodick, G., additional, and Paran, D., additional
- Published
- 2023
- Full Text
- View/download PDF
8. POS1473 ASSESSLE- A NEW TOOL TO ASSESS SLE DISEASE ACTIVITY- THE PATIENTS’ PERSPECTIVE
- Author
-
Paran, D., primary, Ben-Am, M., additional, Mendel, L., additional, Polachek, A., additional, Furer, V., additional, Elalouf, O., additional, Wollman, J., additional, Eviatar, T., additional, Pel, S., additional, Kivity, S., additional, Elkayam, O., additional, and Agmon-Levin, N., additional
- Published
- 2023
- Full Text
- View/download PDF
9. AB0990 OBSTRUCTIVE SLEEP APNEA IS INCREASED IN PATIENTS WITH SPONDYLOARTHRITIS COMPARED TO HEALTHY CONTROLS
- Author
-
Kalish, O., primary, Elkayam, O., additional, Meidan, R., additional, Eviatar, T., additional, Tauman, R., additional, Paran, D., additional, Bieber, A., additional, Furer, V., additional, Polachek, A., additional, Pel, S., additional, Nevo, S., additional, Levartovsky, D., additional, and Elalouf, O., additional
- Published
- 2023
- Full Text
- View/download PDF
10. Immunosuppressive Treatment in Interstitial Lung Disease Secondary to Antisynthetase Syndrome and Systemic Sclerosis - a Multicenter Observational Study
- Author
-
Freund, O., primary, Eviatar, T., additional, Shalmon, T., additional, Schneer, S., additional, Adir, Y., additional, Wand, O., additional, Shitrit, D., additional, Bar-Shai, A., additional, and Unterman, A., additional
- Published
- 2023
- Full Text
- View/download PDF
11. PO.7.144 ASSESSLE- a new tool to assess sle disease activity- the patients’ perspective
- Author
-
Paran, D, primary, Ben-Am, M, additional, Mendel, L, additional, Ari, P, additional, Furer, V, additional, Elalouf, O, additional, Wollman, J, additional, Eviatar, T, additional, Pel, S, additional, Kivity, S, additional, Elkayam, O, additional, and Agmon-Levin, N, additional
- Published
- 2022
- Full Text
- View/download PDF
12. OP0177 IMMUNOGENICITY INDUCED BY TWO AND THREE DOSES OF THE BNT162B2 mRNA VACCINE IN PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES AND IMMUNOCOMPETENT CONTROLS: A LONGITUDINAL MULTI-CENTER STUDY
- Author
-
Furer, V., primary, Eviatar, T., additional, Peleg, H., additional, Hagin, D., additional, Freund, T., additional, Levartovsky, D., additional, Paran, D., additional, Kaufman, I., additional, Broyde, A., additional, Polachek, A., additional, Elalouf, O., additional, Feld, J., additional, Haddad, A., additional, Gazitt, T., additional, Elias, M., additional, Hijaze, N., additional, Kharouf, F., additional, Gertel, S., additional, Nevo, S., additional, Pel, S., additional, Zisman, D., additional, and Elkayam, O., additional
- Published
- 2022
- Full Text
- View/download PDF
13. POS1244 THE EFFECT OF SECUKINUMAB ON THE HUMORAL RESPONSE FOLLOWING TWO AND THREE DOSES OF THE BNT162b2 mRNA VACCINE IN PATIENTS WITH SPONDYLOARTHRITIS
- Author
-
Elkayam, O., primary, Eviatar, T., additional, Peleg, H., additional, Paran, D., additional, Levartovsky, D., additional, Kaufman, I., additional, Broyde, A., additional, Elalouf, O., additional, Polachek, A., additional, Feld, J., additional, Haddad, A., additional, Gazitt, T., additional, Elias, M., additional, Hijaze, N., additional, Aassi, M., additional, Quebe-Fehling, E., additional, Alarcon, I., additional, Pel, S., additional, Zisman, D., additional, and Furer, V., additional
- Published
- 2022
- Full Text
- View/download PDF
14. POS1254 RISK FACTORS FOR SEVERE COVID-19 INFECTION AMONG PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES (AIRD) AND THE IMPACT OF VACCINATIONS - AN ISRAELI, MULTI-CENTER EXPERIENCE
- Author
-
Kharouf, F., primary, Eviatar, T., additional, Braun, M., additional, Pokroy-Shapira, E., additional, Brodavka, M., additional, Agmon-Levin, N., additional, Toledano, K., additional, Oren, S., additional, Lidar, M., additional, Amit Vazina, M., additional, Sabbah, F., additional, Tavor, Y., additional, Breuer, G., additional, Zisman, D., additional, Markovits, D., additional, Dagan, A., additional, Bishara Garzuzi, R., additional, Shifman, O., additional, Giryes, S., additional, Elias, M., additional, Feld, J., additional, Reitblat, T., additional, Gazit, T., additional, Hadad, A., additional, Elkayam, O., additional, Paran, D., additional, Mevorach, D., additional, Balbir-Gurman, A., additional, and Braun-Moscovici, Y., additional
- Published
- 2022
- Full Text
- View/download PDF
15. LB0003 IMMUNOGENICITY AND SAFETY OF THE BNT162b2 mRNA COVID-19 VACCINE IN ADULT PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES AND GENERAL POPULATION: A MULTICENTER STUDY
- Author
-
Furer, V., primary, Eviatar, T., additional, Zisman, D., additional, Peleg, H., additional, Paran, D., additional, Levartovsky, D., additional, Zisapel, M., additional, Elalouf, O., additional, Kaufman, I., additional, Meidan, R., additional, Broyde, A., additional, Polachek, A., additional, Wollman, J., additional, Litinsky, I., additional, Meridor, K., additional, Nochomovitz, H., additional, Silberman, A., additional, Rosenberg, D., additional, Feld, J., additional, Haddad, A., additional, Gazitt, T., additional, Elias, M., additional, Higazi, N., additional, Kharouf, F., additional, Shefer, G., additional, Sharon, O., additional, Pel, S., additional, Nevo, S., additional, and Elkayam, O., additional
- Published
- 2021
- Full Text
- View/download PDF
16. AB0312 INCREASED PREVALENCE OF OBSTRUCTIVE SLEEP APNEA IN INDIVIDUALS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
- Author
-
Meidan, R., primary, Paran, D., additional, Tauman, R., additional, Furer, V., additional, Eviatar, T., additional, Levartovsky, D., additional, Polachek, A., additional, Wollman, J., additional, Padova, H., additional, Zisapel, M., additional, Anouk, M., additional, Seyman, E., additional, Elkayam, O., additional, and Elalouf, O., additional
- Published
- 2021
- Full Text
- View/download PDF
17. POS1206 SEROPREVALENCE OF SARS-CoV-2 ANTIBODIES IN AUTOIMMUNE INFLAMMATORY RHEUMATOLOGIC PATIENTS
- Author
-
Eviatar, T., primary, Levartovsky, D., additional, Furer, V., additional, Polachek, A., additional, Elalouf, O., additional, Zisapel, M., additional, Halperin, T., additional, Turner, D., additional, Paran, D., additional, Pel, S., additional, Nevo, S., additional, and Elkayam, O., additional
- Published
- 2021
- Full Text
- View/download PDF
18. POS1217 THE PATTERN OF COVID 19 PANDEMIC AMONG PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES (AIIRD)
- Author
-
Kharouf, F., primary, Eviatar, T., additional, Braun, M., additional, Pokroy-Shapira, E., additional, Brodavka, M., additional, Agmon-Levin, N., additional, Toledano, K., additional, Oren, S., additional, Lidar, M., additional, Tavor, Y., additional, Amit Vazina, M., additional, Sabbah, F., additional, Breuer, G., additional, Dagan, A., additional, Zisman, D., additional, Markovits, D., additional, Reitblat, T., additional, Giryes, S., additional, Mevorach, D., additional, Paran, D., additional, Elkayam, O., additional, Balbir-Gurman, A., additional, and Braun-Moscovici, Y., additional
- Published
- 2021
- Full Text
- View/download PDF
19. FRI0337 REAL WORLD SECUKINUMAB DRUG-SURVIVAL IN PSORIATIC ARTHRITIS
- Author
-
Eviatar, T., primary, Zisman, D., additional, Lidar, M., additional, Reitblat, T., additional, Balbir-Gurman, A., additional, and Elkayam, O., additional
- Published
- 2020
- Full Text
- View/download PDF
20. OBSTRUCTIVE SLEEP APNEA IS INCREASED IN PATIENTS WITH SPONDYLOARTHRITIS COMPARED TO HEALTHY CONTROLS.
- Author
-
Kalish, O., Elkayam, O., Meidan, R., Eviatar, T., Tauman, R., Paran, D., Bieber, A., Furer, V., Polachek, A., Pel, S., Nevo, S., Levartovsky, D., and Elalouf, O.
- Published
- 2023
- Full Text
- View/download PDF
21. INTERSTITIAL LUNG DISEASE SECONDARY TO ANTI SYNTHETASE SYNDROME AND SYSTEMIC SCLEROSIS: DIFFERENCES IN CHARACTERISTICS AND IMMUNOSUPPRESSIVE TREATMENT RESPONSE.
- Author
-
Eviatar, T., Freund, O., Shalmon, T., Schneer, S., Adir, Y., Wand, O., Shitrit, D., Elkayam, O., Bar-Shai, A., and Unterman, A.
- Published
- 2023
- Full Text
- View/download PDF
22. OMICRON BREAKTHROUGH INFECTIONS AMONG RITUXIMAB AND NON-RITUXIMAB TREATED PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES: A MULTICENTER CONTROLLED STUDY.
- Author
-
Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., Kaufman, I., Broyde, A., Polachek, A., Feld, J., Haddad, A., Gazitt, T., Elias, M., Hijaze, N., Friedlander, Y., and Elkayam, O.
- Published
- 2023
- Full Text
- View/download PDF
23. SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN ISRAEL: GENDER DIFFERENCES IN MANIFESTATIONS, MANAGEMENT AND COMORBIDITIES.
- Author
-
Eviatar, T., Rosenberg, V., Elkayam, O., Chodick, G., and Paran, D.
- Published
- 2023
- Full Text
- View/download PDF
24. ASSESSLE- A NEW TOOL TO ASSESS SLE DISEASE ACTIVITY- THE PATIENTS' PERSPECTIVE.
- Author
-
Paran, D., Ben-Am, M., Mendel, L., Polachek, A., Furer, V., Elalouf, O., Wollman, J., Eviatar, T., Pel, S., Kivity, S., Elkayam, O., and Agmon-Levin, N.
- Published
- 2023
- Full Text
- View/download PDF
25. PW01-010 – The effect of pregnancy on disease course in FMF
- Author
-
Eviatar, T, primary, Zaks, N, additional, Kukuy, OL, additional, Livneh, A, additional, and Lidar, M, additional
- Published
- 2013
- Full Text
- View/download PDF
26. A novel inhibitory pathway of synovial inflammation exerted by glucocorticoids and tumor necrosis factor inhibitors via lymphocyte activation gene-3 up-regulation: an ex-vivo study.
- Author
-
Gertel S, Polachek A, Eviatar T, Elkayam O, and Furer V
- Abstract
Objective: To investigate the impact of glucocorticoids (GCs) and anti-rheumatic drugs on the lymphocyte activation gene-3 (LAG-3) and on programmed cell death-1 (PD-1) expression on synovial and peripheral cells ex-vivo., Methods: Synovial fluid mononuclear cells (SFMCs) from psoriatic arthritis (PsA, n = 26) and rheumatoid arthritis (RA, n = 13) patients, SFCs from osteoarthritis (OA, n = 5) patients and peripheral blood mononuclear cells (PBMCs) of healthy donors (n = 14) were co-cultured with GCs, glucocorticoid receptor antagonist RU486, methotrexate (MTX) and biologics. LAG-3 and PD-1 expressions on immune subsets were analyzed by flow cytometry., Results: GCs in PsA inhibited SFMCs growth vs medium (2.3 ± 0.4X105 vs 5.3 ± 0.7X105, respectively, p < 0.01) and markedly upregulated CD14+LAG-3+ cells (11.7 ± 2.4% vs 0.8 ± 0.3%, p < 0.0001, respectively), but not CD3+LAG-3+ and CD14+PD-1+ cells. MTX had no effect on CD14+LAG-3+ cells (0.7 ± 0.3%). The TNFi inhibitors, infliximab (IFX) and etanercept, but not IL-12/23i, upregulated CD14+LAG-3+ cells vs medium (2.0 ± 0.6% and 1.6 ± 0.4% vs 0.5 ± 0.1%, p < 0.03, respectively). SFMCs growth inhibition in both PsA and RA correlated with CD14+LAG-3+ cell upregulation (r = 0.53, p = 0.03). RU486 inhibited GC-induced CD14+LAG-3+ cell up-regulation in a dose-dependent manner compared with GC alone (5µM 5.3 ± 1.2% and 50µM 1.3 ± 0.5% vs 7.0 ± 1.4%, p < 0.003), but had no significant effect on CD14+LAG-3+ cells co-cultured with IFX. GCs in healthy donors' PBMCs upregulated the immune subsets CD3+LAG-3+, CD14+LAG-3+ and CD14+PD-1+ cells., Conclusion: This study proposes a novel regulatory mechanism of GCs and of TNFi mediated by LAG-3 upregulation in synovial monocytes and PBMCs. LAG-3 modulation may be a promising target for development of novel therapies for inflammatory arthritis., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
27. Cellular immune response to the anti-SARS-CoV-2 BNT162b2 mRNA vaccine in pediatric autoimmune inflammatory rheumatic disease patients and controls.
- Author
-
Eviatar T, Pappo A, Freund T, Friedlander Y, Elkayam O, Hagin D, and Heshin-Bekenstein M
- Subjects
- Humans, Female, Male, Child, Adolescent, Prospective Studies, Autoimmune Diseases immunology, Longitudinal Studies, COVID-19 Vaccines immunology, Spike Glycoprotein, Coronavirus immunology, Immunity, Humoral immunology, CD4-Positive T-Lymphocytes immunology, Interferon-gamma immunology, BNT162 Vaccine immunology, COVID-19 immunology, COVID-19 prevention & control, SARS-CoV-2 immunology, Rheumatic Diseases immunology, Immunity, Cellular, Antibodies, Viral blood, Antibodies, Viral immunology
- Abstract
This paper aims to compare the cellular immune response to the SARS-CoV-2 BNT162b2 vaccine of pediatric patients with autoimmune inflammatory rheumatic disease (pAIIRD) and healthy controls. A prospective longitudinal study was conducted between April 2021 and December 2022 at the Tel Aviv Medical Center. Children <18 years, with pediatric-onset AIIRD and healthy controls, who have received at least two doses of the BNT162b2 vaccine, were included. Humoral response was evaluated by serum levels of anti-SARS-CoV-2 receptor-binding domain antibodies. Cellular response was evaluated by flow cytometry, measuring IFNγ and TNFα production by CD4+ T cells following stimulation with SARS-CoV-2 Spike peptide mix. The study included 20 pAIIRD patients and 11 controls. The mean age of participants was 12.6 ± 2.94 years, with 58.1% females. The cellular response to the BNT162b2 vaccine was statistically similar in both groups. However, the humoral response was statistically lower in pAIIRD compared with the healthy control group. There was no statistically significant correlation between the humoral response and cellular response. During the study period, 43.75% of AIIRD children and 72.7% of controls had a breakthrough COVID-19 infection (P = 0.48). Bivariate models examining the effect of the cellular response and presence of an AIIRD on breakthrough infections found no effect. Compared with healthy controls, pAIIRD demonstrated similar cellular responses. Patients showed reduced humoral response compared with healthy adolescents, but similar breakthrough infection rates. These findings may support the importance of the cellular response in protecting against COVID-19 infections., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Immunology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
28. Ocular and orbital manifestations in VEXAS syndrome.
- Author
-
Abumanhal M, Leibovitch I, Zisapel M, Eviatar T, Edel Y, and Ben Cnaan R
- Subjects
- Humans, Male, Retrospective Studies, Aged, Aged, 80 and over, Middle Aged, Ubiquitin-Activating Enzymes genetics, Myelodysplastic Syndromes genetics, Myelodysplastic Syndromes complications, Myelodysplastic Syndromes diagnosis, Scleritis diagnosis, Scleritis etiology, Eye Diseases etiology, Eye Diseases genetics, Eye Diseases diagnosis, Mutation, Hereditary Autoinflammatory Diseases genetics, Hereditary Autoinflammatory Diseases diagnosis, Hereditary Autoinflammatory Diseases complications, Orbital Diseases etiology, Orbital Diseases diagnosis
- Abstract
Background: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) is a hematoinflammatory disease that typically affects adults. It results from a somatic mutation of the E1 ubiquitin conjugating enzyme encoded by the UBA1 gene. VEXAS is frequently accompanied by myelodysplastic syndrome (MDS). The purpose of this study is to describe the ocular and orbital manifestations of VEXAS patients in a case series in our medical centre., Methods: A retrospective chart review was performed for all patients who were diagnosed with VEXAS syndrome in a tertiary medical centre over two years., Results: Eight patients were identified with VEXAS. In six patients, the diagnosis was confirmed by genomic sequencing. Two patients were identified based on their phenotype. All patients were males. The mean age at diagnosis was 78.7 years. In two patients, the ocular manifestation was the presenting symptom for VEXAS. Seven patients (87.5%) had history of MDS. Systemic inflammation manifestations include: skin rash (n = 5), recurrent fevers (n = 2), relapsing polychondritis (n = 2), pleuritis and pleural effusion (n = 2), poly arteritis nodosa- PAN (n = 1) and thrombophlebitis (n = 1). Seven (87%) patients were presented with periorbital oedema. Three patients showed orbital inflammation. Dacryoadenitis was observed in two patients, and extraocular muscle (EOM) myositis was detected in two patients. Four patients demonstrated ocular inflammation such as: episcleritis, scleritis and anterior uveitis., Conclusion: ocular manifestations in VEXAS include orbital inflammation, dacryoadenitis, myositis, uveitis, scleritis, episcleritis and periorbital oedema. We recommend that in old male patients, with history of haematological disorder, presenting with ocular symptom, VEXAS investigation should be taken into consideration., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
29. Case report: Cerebral sinus vein thrombosis in VEXAS syndrome.
- Author
-
Zisapel M, Seyman E, Molad J, Hallevi H, Mauda-Havakuk M, Jonas-Kimchi T, Elkayam O, and Eviatar T
- Abstract
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic) syndrome is a newly described hemato-inflammatory acquired monogenic entity that presents in adulthood. One of the main features of VEXAS syndrome is a high venous thromboembolism (VTE) burden, with approximately 30-40% experiencing lower extremity deep vein thrombosis and a lower incidence of pulmonary embolism at approximately 10%. To date, VEXAS syndrome has not been associated with rarer forms of VTE such as cerebral sinus vein thrombosis (CSVT) and Budd-Chiari syndrome, which are well-recognized vascular manifestations in Behcet's disease, another autoinflammatory vasculitic disease. Herein, we describe a case of acute severe extensive and fatal CSVT in a patient with VEXAS syndrome. The event occurred during a period of apparently quiescent inflammatory status, while the patient was receiving tocilizumab and a low dose of glucocorticoids. Despite treatment with anticoagulation, high-dose glucocorticoids, endovascular thrombectomy, and intracranial pressure-lowering agents, the patient suffered severe neurologic damage and ultimately succumbed to the condition 3 weeks after the onset of CSVT. To the best of our knowledge, this is the first reported case of CVST in a patient with VEXAS syndrome., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Zisapel, Seyman, Molad, Hallevi, Mauda-Havakuk, Jonas-Kimchi, Elkayam and Eviatar.)
- Published
- 2024
- Full Text
- View/download PDF
30. Effect of Secukinumab and Tumor Necrosis Factor Inhibitors on Humoral Response to BNT162b2 mRNA Vaccine in Patients With Spondyloarthritis Compared to Immunocompetent Controls.
- Author
-
Eviatar T, Furer V, Polachek A, Zisman D, Peleg H, Elalouf O, Levartovsky D, Kaufman I, Broyde A, Haddad A, Feld J, Aassi M, Quebe-Fehling E, Alarcon I, Pel S, Paran D, and Elkayam O
- Subjects
- Humans, Tumor Necrosis Factor Inhibitors therapeutic use, mRNA Vaccines, BNT162 Vaccine, Tumor Necrosis Factor-alpha, Treatment Outcome, Methotrexate therapeutic use, Antirheumatic Agents therapeutic use, Spondylarthritis drug therapy, Arthritis, Rheumatoid drug therapy, COVID-19, Breakthrough Infections, Antibodies, Monoclonal, Humanized
- Abstract
Objective: To assess the humoral response to the BNT162b2 mRNA vaccine among patients with spondyloarthritis (SpA) receiving secukinumab (SEC) compared to those receiving tumor necrosis factor inhibitors (TNFi) and immunocompetent controls., Methods: Consecutive patients with psoriatic arthritis or axial SpA receiving SEC (n = 37) or TNFi (monotherapy, n = 109; + methotrexate [MTX], n = 16), immunocompetent controls (n = 122), and patients with rheumatoid arthritis (RA) receiving TNFi therapy (controls, n = 50) were vaccinated with 2 or 3 doses of the BNT162b2 vaccine. We evaluated humoral response, adverse events, and disease activity, and monitored for breakthrough coronavirus disease 2019 (COVID-19) postvaccination., Results: The 2-dose vaccine regimen induced a comparable seropositive response in all study groups. S1/S2 antibody titers (in binding antibody units/mL; mean [SD]) were higher in the SEC group vs the TNFi + MTX-SpA and TNFi-RA groups (192.5 [68.4] vs 104.6 [46.9], P < 0.001, and 143.1 [81.9], P = 0.004). After 6 months, 96.3%, 96.6%, and 80.9% of the SEC, immunocompetent, and TNFi monotherapy-SpA groups ( P = 0.10), respectively; 66.7% of the TNFi + MTX-SpA group ( P = 0.03); and 63% of the TNFi-RA group ( P = 0.004) remained seropositive. S1/S2 antibody titer decline was steeper in the TNFi groups than the SEC group. After the third dose, 100% of the SpA and immunocompetent and 88.9% of the TNFi-RA ( P = 0.25) groups were seropositive. Rate of breakthrough COVID-19 infection was higher in the TNFi groups than in the SEC group (36-37.5% vs 10.8%). No significant between-group differences were observed for postvaccination disease activity and adverse events., Conclusion: SEC did not interfere with the immunogenic response to BNT162b2 vaccine in patients with SpA; however, TNFi therapy was associated with lower S1/S2-antibody titers, faster decline, and higher rate of breakthrough infections., (Copyright © 2024 by the Journal of Rheumatology.)
- Published
- 2024
- Full Text
- View/download PDF
31. Heart Valve Surgery in Antiphospholipid Syndrome Patients-Morbidity and Mortality.
- Author
-
Eviatar T, Niznik S, Elkayam O, Ben-Gal Y, Shavit R, Raanani E, Agmon-Levin N, and Paran D
- Abstract
Objectives: To assess valve surgery outcomes in antiphospholipid syndrome (APS)., Methods: A retrospective study assessing complications and mortality rate and possible factors associated with adverse outcomes of APS patients undergoing valve surgery in two tertiary medical centers., Results: Twenty-six APS patients (median age at surgery 47.5 years) who underwent valve surgery were detected, of whom 11 (42.3%) had secondary APS. The mitral valve was most commonly involved ( n = 15, 57.7%). A valve replacement was performed in 24 operations (92.3%), 16 of which (66.7%) were mechanical valves. Fourteen (53.8%) patients sustained severe complications, and four of them died. The presence of mitral regurgitation (MR) was associated with severe complications and mortality (odds ratio (95% confidence interval) 12.5 (1.85-84.442), p = 0.008, for complications. All deceased patients had MR ( p = 0.033). The presence of Libman-Sacks endocarditis (LSE) (7.333 (1.272-42.294), p = 0.045), low C3 (6.667 (1.047-42.431), p = 0.05) and higher perioperative prednisone doses (15 ± 21.89 vs. 1.36 ± 3.23 mg/day, p = 0.046) were also associated with complications. A lower glomerular filtration rate (GFR) was associated with mortality (30.75 ± 19.47 vs. 70.68 ± 34.44 mL/min, p = 0.038)., Conclusions: Significant morbidity and mortality were observed among APS patients undergoing valve surgery. MR was associated with mortality and complications. LSE, low complement and higher doses of corticosteroids were associated with complications, while a low GFR was associated with mortality.
- Published
- 2023
- Full Text
- View/download PDF
32. A deep look into the storm: Israeli multi-center experience of coronavirus disease 2019 (COVID-19) in patients with autoimmune inflammatory rheumatic diseases before and after vaccinations.
- Author
-
Kharouf F, Eviatar T, Braun M, Pokroy-Shapira E, Brodavka M, Zloof Y, Agmon-Levin N, Toledano K, Oren S, Lidar M, Zisman D, Tavor Y, Amit-Vazina M, Sabbah F, Breuer GS, Dagan A, Beshara-Garzuzi R, Markovits D, Elias M, Feld J, Tayer-Shifman O, Gazitt T, Reitblatt T, Rubin L, Haddad A, Giryes S, Paran D, Peleg H, Molad Y, Elkayam O, Mevorach D, Balbir-Gurman A, and Braun-Moscovici Y
- Subjects
- Humans, Israel epidemiology, SARS-CoV-2, COVID-19 Testing, COVID-19 Vaccines, Vaccination, COVID-19 epidemiology, COVID-19 prevention & control, Rheumatic Diseases epidemiology
- Abstract
Objective: We aimed to characterize the course of COVID-19 in autoimmune inflammatory rheumatic disease (AIIRD) patients in Israel, taking into consideration several remarkable aspects, including the outcomes of the different outbreaks, the effect of vaccination campaigns, and AIIRD activity post-recovery., Methods: We established a national registry of AIIRD patients diagnosed with COVID-19, including demographic data, AIIRD diagnosis, duration and systemic involvement, comorbidities, date of COVID-19 diagnosis, clinical course, and dates of vaccinations. COVID-19 was diagnosed by a positive SARS-CoV-2 polymerase chain reaction., Results: Israel experienced 4 outbreaks of COVID-19 until 30.11.2021. The first three outbreaks (1.3.2020 - 30.4.2021) comprised 298 AIIRD patients. 64.9% had a mild disease and 24.2% had a severe course; 161 (53.3%) patients were hospitalized, 27 (8.9%) died. The 4
th outbreak (delta variant), starting 6 months after the beginning of the vaccination campaign comprised 110 patients. Despite similar demographic and clinical characteristics, a smaller proportion of AIIRD patients had negative outcomes as compared to the first 3 outbreaks, with regards to severity (16 patients,14.5%), hospitalization (29 patients, 26.4%) and death (7 patients, 6.4%). COVID-19 did not seem to influence the AIIRD activity 1-3 months post-recovery., Conclusions: COVID-19 is more severe and has an increased mortality in active AIIRD patients with systemic involvement, older age and comorbidities. Vaccination with 3 doses of the mRNA vaccine against SARS-CoV-2 protected from severe COVID-19, hospitalization and death during the 4th outbreak. The pattern of spread of COVID-19 in AIIRD patients was similar to the general population., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Kharouf, Eviatar, Braun, Pokroy-Shapira, Brodavka, Zloof, Agmon-Levin, Toledano, Oren, Lidar, Zisman, Tavor, Amit-Vazina, Sabbah, Breuer, Dagan, Beshara-Garzuzi, Markovits, Elias, Feld, Tayer-Shifman, Gazitt, Reitblatt, Rubin, Haddad, Giryes, Paran, Peleg, Molad, Elkayam, Mevorach, Balbir-Gurman and Braun-Moscovici.)- Published
- 2023
- Full Text
- View/download PDF
33. Systemic Lupus Erythematous and Obstructive Sleep Apnea: A Possible Association.
- Author
-
Meidan R, Elalouf O, Tauman R, Furer V, Polachek A, Wollman J, Eviatar T, Zisapel M, Levartovsky D, Seyman E, Elkayam O, and Paran D
- Abstract
Marked fatigue is common in patients with systemic lupus erythematosus (SLE). This study aimed to assess the association of sleep disorders, including obstructive sleep apnea (OSA), with SLE. Forty-two consecutive patients with SLE and 20 healthy controls were recruited and underwent a one-night ambulatory sleep examination. They completed questionnaires, including the Pittsburgh Sleep Quality Index (PSQI) and Functional Assessment of Chronic Illness Therapy (FACIT). SLE disease activity and damage were assessed by the SLE Disease Activity Index 2000 (SLEDAI-2K) and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index (SDI). A significantly increased apnea/hypopnea index was noted in the SLE group compared to healthy controls ( p = 0.004). SLE patients had higher rates of moderate-to-severe OSA ( p = 0.04), PSQI ( p = 0.001), and FACIT scores ( p = 0.0008). Multivariate analysis revealed that the SDI was associated with OSA ( p = 0.03). There was a positive association between SLEDAI-2K and moderate-to-severe OSA ( p = 0.03). Patients with SLE had an increased prevalence of OSA and poorer quality of sleep compared to healthy controls. Our findings suggest that active disease and accumulated damage may be associated with OSA. These findings highlight the importance of identifying the presence of OSA in patients with SLE.
- Published
- 2023
- Full Text
- View/download PDF
34. Development of Autoantibodies Following BNT162b2 mRNA COVID-19 Vaccination and Their Association with Disease Flares in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) and the General Population: Results of 1-Year Prospective Follow-Up Study.
- Author
-
Gazitt T, Eviatar T, Shear J, Meidan R, Furer V, Feld J, Haddad A, Elias M, Hijazi N, Stein N, Shaked Mishan P, Zetser A, Peleg H, Elkayam O, and Zisman D
- Abstract
Development of autoantibodies following BNT162b2 mRNA COVID-19 vaccination and their association with disease flares in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) and the general population: results of 1-year prospective follow-up study. We conducted a prospective study aimed at investigating the incidence of appearance of autoantibodies (antinuclear, antiphospholipid, and rheumatoid factor) in the sera of 463 adult patients with AIIRD compared to 55 controls from the general population prior to, and following the second and third vaccine doses, and at 1-year of follow-up. Pre- and post-vaccination disease activity indices and the association of autoantibodies with rheumatic disease flares and new onset AIIRD were examined. Autoantibody development of any type in AIIRD patients vs. the controls was 4.0% (vs. 6.7%, p = 0.423) following two vaccine doses and 7.6% (vs. 0%, p = 0.152) after three doses. There was no significant difference in sex, age, or disease-type among individuals with and without autoantibody development, regardless of the immunosuppressant use. More patients developed autoantibodies following the third than the second vaccine dose ( p = 0.004). Disease flares occurred in 5.8% and 7.2% of AIIRD patients following second and third vaccine doses, respectively, with autoantibody production increasing the risk of flares following the second ( p = 0.002) and third ( p = 0.004) vaccine doses. BNT162b2 vaccination resulted in the development of autoantibodies in a minority of AIIRD patients and controls. Autoantibody development was associated with disease flares in patients, but no new-onset autoimmunity was observed.
- Published
- 2023
- Full Text
- View/download PDF
35. Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study.
- Author
-
Furer V, Eviatar T, Freund T, Peleg H, Paran D, Levartovsky D, Kaufman I, Broyde A, Elalouf O, Polachek A, Feld J, Haddad A, Gazitt T, Elias M, Higazi N, Kharouf F, Gertel S, Pel S, Nevo S, Hagin D, Zisman D, and Elkayam O
- Subjects
- Abatacept therapeutic use, Adult, Antibodies, Viral, Antirheumatic Agents therapeutic use, Humans, Immunoglobulin G therapeutic use, Janus Kinases, Methotrexate therapeutic use, Prospective Studies, Rituximab therapeutic use, Autoimmune Diseases complications, Autoimmune Diseases drug therapy, BNT162 Vaccine immunology, COVID-19 prevention & control, Immunogenicity, Vaccine, Rheumatic Diseases drug therapy
- Abstract
Objectives: To evaluate long-term kinetics of the BNT162b2 mRNA vaccine-induced immune response in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) and immunocompetent controls., Methods: A prospective multicentre study investigated serum anti-SARS-CoV-2 S1/S2 IgG titre at 2-6 weeks (AIIRD n=720, controls n=122) and 6 months (AIIRD n=628, controls n=116) after the second vaccine, and 2-6 weeks after the third vaccine dose (AIIRD n=169, controls n=45). T-cell immune response to the third vaccine was evaluated in a small sample., Results: The two-dose vaccine regimen induced a higher humoral response in controls compared with patients, postvaccination seropositivity rates of 100% versus 84.72%, p<0.0001, and 96.55% versus 74.26%, p<0.0001 at 2-6 weeks and at 6 months, respectively. The third vaccine dose restored the seropositive response in all controls and 80.47% of patients with AIIRD, p=0.0028. All patients treated with methotrexate monotherapy, anticytokine biologics, abatacept and janus kinase (JAK) inhibitors regained the humoral response after the third vaccine, compared with only a third of patients treated with rituximab, entailing a 16.1-fold risk for a negative humoral response, p≤0.0001. Cellular immune response in rituximab-treated patients was preserved before and after the third vaccine and was similar to controls. Breakthrough COVID-19 rate during the Delta surge was similar in patients and controls, 1.83% versus 1.43%, p=1., Conclusions: The two-dose BNTb262 regimen was associated with similar clinical efficacy and similar waning of the humoral response over 6 months among patients with AIIRD and controls. The third vaccine dose restored the humoral response in all of the controls and the majority of patients., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
36. Seroprevalence of SARS-CoV-2 antibodies in patients with autoimmune inflammatory rheumatic diseases.
- Author
-
Eviatar T, Furer V, Polachek A, Levartovsky D, Elalouf O, Zisapel M, Halperin T, Turner D, Paran D, Pel S, Nevo S, and Elkayam O
- Subjects
- Antibodies, Viral, Cross-Sectional Studies, Humans, Immunoglobulin G, SARS-CoV-2, Seroepidemiologic Studies, COVID-19 epidemiology, Rheumatic Diseases diagnosis, Rheumatic Diseases drug therapy, Rheumatic Diseases epidemiology, Rheumatic Fever
- Abstract
Objectives: To assess the prevalence of anti-SARS-CoV-2 antibodies in autoimmune inflammatory rheumatic disease (AIIRD) patients, and to define clinical factors associated with seropositivity., Methods: A cross sectional study was conducted at a tertiary rheumatology department in Israel. Consecutive patients completed a questionnaire and were tested for SARS-CoV-2 anti-nucleoprotein IgG (N-IgG). If this was positive, an anti-S1/S2 spike IgG (S-IgG) test was done. If both were positive, the patient was considered seropositive. Seropositive patients were retested after 3 months., Results: The study included 572 AIIRD patients. Thirty patients were found seropositive, for a seroprevalence of 5.24%. The seropositive rate was significantly lower for patients treated with immunosuppressive medications (3.55%, p≤0.01), and specifically for patients treated with biologic disease-modifying anti-rheumatic drugs (bDMARDs) (2.7%, p≤0.05). These associations remained significant in the multivariate regressions adjusting for age, sex and exposure to a known COVID-19 patient. A second serology test 3 months later was collected in 21 of the 30 seropositive patients. In a mean±standard deviation (SD) of 166.63±40.76 days between PCR and second serology, 85% were still positive for N-IgG, and 100% were still positive for S-IgG, with a higher mean±SD titre compared to the first S-IgG (166.77±108.77 vs. 132.44±91.18, respectively, p≤0.05)., Conclusions: Humoral response to SARS-CoV-2 in AIIRD patients may be affected be immunosuppressive treatment, especially bDMARDs. In patients with AIIRD, titres of SARS-CoV-2 IgG antibodies, especially N-IgG antibodies, fade with time, while S-IgG antibodies persist.
- Published
- 2022
- Full Text
- View/download PDF
37. Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab.
- Author
-
Furer V, Eviatar T, Zisman D, Peleg H, Braun-Moscovici Y, Balbir-Gurman A, Paran D, Levartovsky D, Zisapel M, Elalouf O, Kaufman I, Broyde A, Polachek A, Feld J, Haddad A, Gazitt T, Elias M, Higazi N, Kharouf F, Pel S, Nevo S, and Elkayam O
- Abstract
Treatment with rituximab (RTX) blunts SARS-CoV-2 vaccination-induced humoral response. We sought to identify predictors of a positive immunogenic response to the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases (AIIRD) treated with RTX (AIIRD-RTX). We analyzed 108 AIIRD-RTX patients and 122 immunocompetent controls vaccinated with BNT162b2 mRNA participating in a multicenter vaccination study. Immunogenicity was defined by positive anti-SARS-CoV-2 S1/S2 IgG. We used a stepwise backward multiple logistic regression to identify predicting factors for a positive immunogenic response to vaccination and develop a predicting calculator, further validated in an independent cohort of AIIRD-RTX BNT162b2 mRNA vaccinated patients ( n = 48). AIIRD-RTX patients who mounted a seropositive immunogenic response significantly differed from patients who did not by a lower number of RTX courses (median (range) 3 (1-10) vs. 5 (1-15), p = 0.007; lower cumulative RTX dose (mean ± SD) 6943.11 ± 5975.74 vs. 9780.95 ± 7240.12 mg, p = 0.033; higher IgG level prior to last RTX course (mean ± SD), 1189.78 ± 576.28 vs. 884.33 ± 302.31 mg/dL, p = 0.002), and extended interval between RTX treatment and vaccination, 469.82 ± 570.39 vs. 162.08 ± 160.12 days, p = 0.0009, respectively. Patients with ANCA-associated vasculitis and inflammatory myositis had a low likelihood of a seropositive immunogenic response compared to patients with rheumatoid arthritis, odds ratio (OR) 0.209, 95% confidence interval (CI) 0.046-0.96, p = 0.044 and OR 0.189, 95% CI 0.036-0.987, p = 0.048, respectively. Based on these findings, we constructed a calculator predicting the probability of a seropositive immunogenic response following BNT162b2 mRNA vaccination which performed with 90.5% sensitivity, 59.3% specificity, and 63.3% positive and 88.9% negative predictive values. In summary, the predicting calculator could guide clinicians for optimal timing of BNT162b2 mRNA vaccination in AIIRD-RTX patients.
- Published
- 2022
- Full Text
- View/download PDF
38. Concurrent myopathy and inflammatory cardiac disease in COVID-19 patients: a case series and literature review.
- Author
-
Freund O, Eviatar T, and Bornstein G
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Retrospective Studies, SARS-CoV-2, COVID-19 complications, COVID-19 epidemiology, Muscular Diseases complications, Muscular Diseases epidemiology, Myocarditis epidemiology, Myocarditis etiology
- Abstract
Adult COVID-19 patients can present with acute muscle and/or cardiac involvement. Our study aims to describe the incidence and characteristics of patients with the co-occurrence of COVID-19 myopathy and inflammatory cardiac disease. We retrospectively reviewed all COVID-19 patients admitted to a large tertiary center to assess the co-occurrence of myopathy and inflammatory cardiac disease. We conducted a literature review of prior relevant case reports. There were three COVID-19 patients with concurrent involvement from our center and five cases in the published literature. Overall, mean age was 57.7 ± 16, four were females (50%) and only two patients (25%) had major relevant comorbidities. Muscle involvement included rhabdomyolysis or myositis and cardiac involvement included myocarditis or pericarditis. Most patients (75%) had no respiratory COVID-19 symptoms. Troponin and creatine phosphokinase levels were higher than twofold of the upper limit of normal for all patients. Steroids were used in the treatment of most patients (75%). All patients had a resolution or improvement of their extra-pulmonary involvement while two (25%) deteriorated due to COVID-19 pneumonia. The incidence for this co-occurrence is 0.07% among hospitalized COVID-19 patients. Patients with these rare COVID-19 simultaneous manifestations have distinct features. They are generally younger, present with extra-pulmonary symptoms and do not have severe respiratory compromise. An underdiagnosis causing treatment delay is possible. Further study is needed., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
39. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
- Author
-
Spitzer A, Angel Y, Marudi O, Zeltser D, Saiag E, Goldshmidt H, Goldiner I, Stark M, Halutz O, Gamzu R, Slobodkin M, Amrami N, Feigin E, Elbaz M, Furman M, Bronstein Y, Chikly A, Eshkol A, Furer V, Mayer T, Meijer S, Melloul A, Mizrahi M, Yakubovsky M, Rosenberg D, Safir A, Spitzer L, Taleb E, Elkayam O, Silberman A, Eviatar T, Elalouf O, Levinson T, Pozyuchenko K, Itzhaki-Alfia A, Sprecher E, Ben-Ami R, and Henig O
- Subjects
- Adult, Aged, BNT162 Vaccine immunology, COVID-19 diagnosis, COVID-19 prevention & control, COVID-19 Nucleic Acid Testing, Female, Humans, Immunization, Secondary, Immunoglobulin G blood, Incidence, Israel epidemiology, Male, Middle Aged, Proportional Hazards Models, Prospective Studies, SARS-CoV-2 immunology, Spike Glycoprotein, Coronavirus immunology, Antibodies, Viral blood, BNT162 Vaccine administration & dosage, COVID-19 epidemiology, COVID-19 Vaccines immunology, Health Personnel statistics & numerical data, Vaccine Efficacy
- Abstract
Importance: Administration of a BNT162b2 booster dose (Pfizer-BioNTech) to fully vaccinated individuals aged 60 years and older was significantly associated with lower risk of SARS-CoV-2 infection and severe illness. Data are lacking on the effectiveness of booster doses for younger individuals and health care workers., Objective: To estimate the association of a BNT162b2 booster dose with SARS-CoV-2 infections among health care workers who were previously vaccinated with a 2-dose series of BNT162b2., Design, Setting, and Participants: This was a prospective cohort study conducted at a tertiary medical center in Tel Aviv, Israel. The study cohort included 1928 immunocompetent health care workers who were previously vaccinated with a 2-dose series of BNT162b2, and had enrolled between August 8 and 19, 2021, with final follow-up reported through September 20, 2021. Screening for SARS-CoV-2 infection was performed every 14 days. Anti-spike protein receptor binding domain IgG titers were determined at baseline and 1 month after enrollment. Cox regression with time-dependent analysis was used to estimate hazard ratios of SARS-CoV-2 infection between booster-immunized status and 2-dose vaccinated (booster-nonimmunized) status., Exposures: Vaccination with a booster dose of BNT162b2 vaccine., Main Outcomes and Measures: The primary outcome was SARS-CoV-2 infection, as confirmed by reverse transcriptase-polymerase chain reaction., Results: Among 1928 participants, the median age was 44 years (IQR, 36-52 years) and 1381 were women (71.6%). Participants completed the 2-dose vaccination series a median of 210 days (IQR, 205-213 days) before study enrollment. A total of 1650 participants (85.6%) received the booster dose. During a median follow-up of 39 days (IQR, 35-41 days), SARS-CoV-2 infection occurred in 44 participants (incidence rate, 60.2 per 100 000 person-days); 31 (70.5%) were symptomatic. Five SARS-CoV-2 infections occurred in booster-immunized participants and 39 in booster-nonimmunized participants (incidence rate, 12.8 vs 116 per 100 000 person-days, respectively). In a time-dependent Cox regression analysis, the adjusted hazard ratio of SARS-CoV-2 infection for booster-immunized vs booster-nonimmunized participants was 0.07 (95% CI, 0.02-0.20)., Conclusions and Relevance: Among health care workers at a single center in Israel who were previously vaccinated with a 2-dose series of BNT162b2, administration of a booster dose compared with not receiving one was associated with a significantly lower rate of SARS-CoV-2 infection over a median of 39 days of follow-up. Ongoing surveillance is required to assess durability of the findings.
- Published
- 2022
- Full Text
- View/download PDF
40. Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis.
- Author
-
Eviatar T, Zisman D, Gendelman O, Reitblat T, Balbir-Gurman A, Mashiach T, Almog R, and Elkayam O
- Subjects
- Antibodies, Monoclonal, Humanized, Humans, Treatment Outcome, Tumor Necrosis Factor Inhibitors, Tumor Necrosis Factor-alpha therapeutic use, Antirheumatic Agents adverse effects, Arthritis, Psoriatic diagnosis, Arthritis, Psoriatic drug therapy, Pharmaceutical Preparations
- Abstract
Objectives: To prospectively study real-world efficacy and safety of secukinumab in psoriatic arthritis (PsA) patients from the Israeli registry of inflammatory diseases., Methods: PsA patients fulfilling the CASPAR criteria were included in the analysis from 2010 to 2019. The primary endpoint was secukinumab drug retention compared to other TNF-α inhibitors (TNFi). Bivariate and multivariate analyses were made by Cox regression analysis. Drug retention according to treatment line was examined with Kaplan-Meier curves., Results: Included were 404 PsA patients who had 709 treatment courses during the study period. Ninety patients had been treated with secukinumab (22%). The secukinumab-treated patients were significantly older and their disease duration was longer. Secukinumab was less likely to be the first line of treatment compared to TNFi. Secukinumab had a drug retention comparable to TNFi, and a better drug retention than TNFi among biologic-experienced patients. Neither methotrexate combination nor body mass index affected the inefficacy event rate. Secukinumab had a similar rate of adverse events as TNFi., Conclusions: This multicentre real-world study demonstrated that secukinumab had a drug retention comparable to TNFi. Secukinumab had a better drug retention than TNFi among biologic-experienced patients. IL-17 inhibition is an effective mechanism of action to treat PsA in real life.
- Published
- 2022
- Full Text
- View/download PDF
41. Quality evaluation of the underlying evidence in the updated treatment recommendations for systemic lupus erythematosus.
- Author
-
Yavne Y, Edel Y, Berman J, Eviatar T, and Shepshelovich D
- Subjects
- Humans, Evidence-Based Medicine, Lupus Erythematosus, Systemic therapy
- Abstract
Objectives: SLE is a multisystem autoimmune disorder known for its broad clinical spectrum. Recently, the European, British and Latin American rheumatology professional societies [EULAR, British Society for Rheumatology (BSR) and Pan-American League of Associations of Rheumatology (PANLAR)] published updated recommendations for SLE management. The objective of this study was to characterize the data supporting the updated recommendations, with the goal of highlighting areas that could benefit from additional high-quality research., Methods: References were compiled from the recently published EULAR, BSR and PANLAR SLE treatment recommendations. Data collected from each study included publication year, treatment regimen, study design, sample size, inclusion and exclusion criteria and relevant SLE diagnostic criteria. Studies with less than 10 patients and those that did not specify the SLE diagnostic criteria used were excluded., Results: Altogether, 250 studies were included in this study. The majority were prospective and retrospective cohorts (72%), with only a small percentage of randomized controlled trials (28%). The median (interquartile range) number of patients included was 37 (19-86). The revised ACR 1982 criteria were the most commonly used criteria for SLE diagnosis (52%), followed by the revised ACR criteria from 1997 (27%). Only a small proportion of studies included the use of disease activity scores when defining study population (15%)., Conclusion: Our study has indicated a scarcity of sufficiently powered high-quality research referenced in the recently published SLE treatment guidelines. Well-designed large-scale studies utilizing the updated 2019 SLE diagnostic criteria are needed to better inform healthcare professionals caring for patients with SLE., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
42. Role of ultrasound for assessment of psoriatic arthritis patients with fibromyalgia.
- Author
-
Polachek A, Furer V, Zureik M, Nevo S, Mendel L, Levartovsky D, Wollman J, Aloush V, Tzemach R, Elalouf O, Anouk M, Berman M, Kaufman I, Carmi O, Lahat Y, Eviatar T, Padova H, Sarbagil-Maman H, Borok S, Broyde A, Eder L, Paran D, and Elkayam O
- Subjects
- Adult, Aged, Arthritis, Psoriatic complications, Arthritis, Psoriatic physiopathology, Case-Control Studies, Enthesopathy diagnostic imaging, Enthesopathy physiopathology, Female, Fibromyalgia complications, Humans, Male, Middle Aged, Synovitis diagnostic imaging, Synovitis physiopathology, Tenosynovitis diagnostic imaging, Tenosynovitis physiopathology, Arthritis, Psoriatic diagnostic imaging, Fibromyalgia physiopathology, Ultrasonography
- Abstract
Objective: To investigate whether ultrasonography (US), as an objective imaging modality, can optimise the evaluation of disease activity in psoriatic arthritis (PsA) patients with concomitant fibromyalgia syndrome (FMS)., Methods: The study population included 156 consecutive PsA patients who were recruited prospectively and fulfilled the ClASsification criteria for Psoriatic ARthritis criteria. The patients underwent complete clinical evaluation including assessment of fulfilment of the 2016 fibromyalgia classification criteria. All of the patients underwent US evaluation including 52 joints, 40 tendons and 14 entheses. The US score was based on the summation of a semiquantitative score (including synovitis, tenosynovitis and enthesitis). Scoring was performed by a sonographer blinded to the clinical data. Spearman's correlation coefficient and multivariate linear regression models were used to examine the association of FMS with clinical and the US scores., Results: Forty-two patients (26.9%) with coexisting PsA and FMS were compared with 114 (73.1%) PsA patients without FMS. Patients with PsA and FMS had significantly increased scores for clinical composite indices, including non-Minimal Disease Activity, Composite Psoriatic Disease Activity Index (CPDAI), Disease Activity for Psoriatic Arthritis (DAPSA) and Psoriatic Arthritis Disease Activity Score (PASDAS) (p<0.001). In contrast, the total US score and its subcategories were similar for those with and without FMS. The total US score significantly correlated with CPDAI, DAPSA and PASDAS (p<0.001) in the PsA without FMS but not in the PsA with FMS group. FMS was significantly associated with higher clinical scores (p<0.001) but not with the US score (multivariable linear regression models)., Conclusions: US has significantly greater value than composite clinical scores in the assessment of disease activity in PsA patients with FMS., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
43. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
- Author
-
Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, Zisapel M, Elalouf O, Kaufman I, Meidan R, Broyde A, Polachek A, Wollman J, Litinsky I, Meridor K, Nochomovitz H, Silberman A, Rosenberg D, Feld J, Haddad A, Gazzit T, Elias M, Higazi N, Kharouf F, Shefer G, Sharon O, Pel S, Nevo S, and Elkayam O
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral blood, Antibodies, Viral immunology, Autoimmune Diseases drug therapy, BNT162 Vaccine, COVID-19 Vaccines adverse effects, Female, Humans, Immunoglobulin G blood, Immunoglobulin G immunology, Immunosuppressive Agents therapeutic use, Male, Middle Aged, Rheumatic Diseases drug therapy, SARS-CoV-2, Young Adult, Autoimmune Diseases immunology, COVID-19 prevention & control, COVID-19 Vaccines immunology, Immunocompromised Host immunology, Immunogenicity, Vaccine immunology, Rheumatic Diseases immunology
- Abstract
Introduction: Vaccination represents a cornerstone in mastering the COVID-19 pandemic. Data on immunogenicity and safety of messenger RNA (mRNA) vaccines in patients with autoimmune inflammatory rheumatic diseases (AIIRD) are limited., Methods: A multicentre observational study evaluated the immunogenicity and safety of the two-dose regimen BNT162b2 mRNA vaccine in adult patients with AIIRD (n=686) compared with the general population (n=121). Serum IgG antibody levels against SARS-CoV-2 spike S1/S2 proteins were measured 2-6 weeks after the second vaccine dose. Seropositivity was defined as IgG ≥15 binding antibody units (BAU)/mL. Vaccination efficacy, safety, and disease activity were assessed within 6 weeks after the second vaccine dose., Results: Following vaccination, the seropositivity rate and S1/S2 IgG levels were significantly lower among patients with AIIRD versus controls (86% (n=590) vs 100%, p<0.0001 and 132.9±91.7 vs 218.6±82.06 BAU/mL, p<0.0001, respectively). Risk factors for reduced immunogenicity included older age and treatment with glucocorticoids, rituximab, mycophenolate mofetil (MMF), and abatacept. Rituximab was the main cause of a seronegative response (39% seropositivity). There were no postvaccination symptomatic cases of COVID-19 among patients with AIIRD and one mild case in the control group. Major adverse events in patients with AIIRD included death (n=2) several weeks after the second vaccine dose, non-disseminated herpes zoster (n=6), uveitis (n=2), and pericarditis (n=1). Postvaccination disease activity remained stable in the majority of patients., Conclusion: mRNA BNTb262 vaccine was immunogenic in the majority of patients with AIIRD, with an acceptable safety profile. Treatment with glucocorticoids, rituximab, MMF, and abatacept was associated with a significantly reduced BNT162b2-induced immunogenicity., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
44. Prevalence of COVID-19 and seroprevalence to SARS-CoV-2 in a rheumatologic patient population from a tertiary referral clinic in Israel.
- Author
-
Eviatar T, Elalouf O, Furer V, Goldstein-Lahat Y, Paran Y, Pel S, Nevo S, Zisapel M, Alcalay Y, and Elkayam O
- Subjects
- Antibodies, Viral, Cross-Sectional Studies, Humans, Israel, Prevalence, Referral and Consultation, SARS-CoV-2, Seroepidemiologic Studies, Arthritis, Rheumatoid, COVID-19
- Abstract
Background: It is unclear if the prevalence of COVID-19 in rheumatologic patients is similar to that of the general population. There are no reports of seroprevalence of SARS-CoV-2 in these patients., Aims: To investigate prevalence of COVID-19 cases and seroprevalence among rheumatologic patients and the risk factors for infection., Methods: A cross-sectional study in a rheumatologic population. An online questionnaire was sent on 31 April 2020. Blood samples from 20% sample of patients were drawn for SARS-CoV-2 antibodies. Patients were divided based on autoimmune (AI) diagnosis. Prevalence of COVID-19 by nasopharyngeal swab and by serology (seroprevalence) was compared to national data. Risk factors for infection of SARS-CoV-2 were assessed., Results: The study group included 1204 patients, 74.5% had an AI diagnosis. The prevalence of COVID-19 was 0.16% in the rheumatologic patient population and 0.22% in the AI group, which was not different from prevalence in Israel on 4 May 2020 (0.18%, P = 0.912 and P = 0.759 respectively). Serologic tests were performed in 242 patients, of which five were found positive pointing to a seroprevalence of 2.07%. Exposure to a known COVID-19 patient was the only significant risk factor for being positive by swab or by serology. AI diagnosis, immunosuppression, corticosteroid, hydroxychloroquine did not influence the risk., Conclusions: The prevalence of COVID-19 in a population of rheumatologic patients was similar to that of the general population. Mild/asymptomatic cases may be prevalent according to serologic tests. The major risk factor for infection is exposure to a known case of COVID-19, and immunosuppression did not play a role in the risk of infection., (© 2021 Royal Australasian College of Physicians.)
- Published
- 2021
- Full Text
- View/download PDF
45. Paraneoplastic Dactylitis Leading to the Diagnosis of Ovarian Cancer.
- Author
-
Eviatar T and Elkayam O
- Subjects
- Carcinoma, Ovarian Epithelial therapy, Chemotherapy, Adjuvant, Diagnosis, Differential, Female, Finger Joint diagnostic imaging, Follow-Up Studies, Humans, Hysterectomy methods, Middle Aged, Multimodal Imaging, Ovarian Neoplasms therapy, Ovariectomy methods, Paraneoplastic Syndromes diagnostic imaging, Risk Assessment, Treatment Outcome, Arthritis diagnosis, Carcinoma, Ovarian Epithelial diagnosis, Finger Joint physiopathology, Ovarian Neoplasms diagnosis, Paraneoplastic Syndromes diagnosis
- Published
- 2019
46. Diabetic Retinopathy -Incidence And Risk Factors In A Community Setting- A Longitudinal Study.
- Author
-
Shani M, Eviatar T, Komaneshter D, and Vinker S
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2 mortality, Female, Humans, Incidence, Kidney Failure, Chronic etiology, Longitudinal Studies, Male, Middle Aged, Myocardial Ischemia etiology, Retrospective Studies, Risk Factors, Young Adult, Diabetes Mellitus, Type 2 complications, Diabetic Retinopathy epidemiology
- Abstract
Aim: To evaluate the natural history of diabetic retinopathy (DR) in diabetic patients and to assess long term risk for other chronic diseases associated with DR., Methods: Retrospective, community-based study. Diabetics who underwent their first fundoscopic examination during 2000-2002, and had at least one follow- up examination by the end of 2007 were included. The primary outcome was the development of DR (proliferative diabetic retinopathy (PDR), non PDR (NPDR) or macular edema. Patients were followed for another 9 years for documentation of new diagnosis of related diseases., Results: 516 patients' (1,032 eyes) records were included and were followed first for an average of 4.15 ± 1.27 years. During follow-up, 28 (2.7%) of the total 1,032 eyes examined were diagnosed with PDR. An additional 194 (18.8%) eyes were diagnosed with new NPDR. The cumulative incidence of NPDR was 310/1,032 (30.0%). All the patients who developed PDR had prior NDPR. By the end of the 9 years extended follow up, patients with NPDR had a greater risk for developing chronic renal failure HR = 1.71 (1.14-2.56), ischemic heart disease HR = 1.57 (1.17-2.09), and had an increased mortality rate HR = 1.26 (1.02-1.57) Conclusion: DR is associated with a higher rate of diabetes complications. Patients with DR should be followed more closely. Key points During a mean follow-up of 4.5 years, the cumulative incidence of diabetic retinopathy in a community cohort was 18.8%. NDPR (non-proliferative diabetic retinopathy) is a predictor of PDR (proliferative diabetic retinopathy). In a real life setting NPDR is a marker of a poorer prognosis. Patients with NDPR should be monitored more closely.
- Published
- 2018
- Full Text
- View/download PDF
47. Nocardiosis: a 15-year experience in a tertiary medical center in Israel.
- Author
-
Rosman Y, Grossman E, Keller N, Thaler M, Eviatar T, Hoffman C, and Apter S
- Subjects
- Adrenal Cortex Hormones adverse effects, Adult, Aged, Amikacin therapeutic use, Carbapenems therapeutic use, Ceftriaxone therapeutic use, Cohort Studies, Encephalitis drug therapy, Encephalitis epidemiology, Female, Humans, Israel epidemiology, Male, Middle Aged, Nocardia Infections drug therapy, Nocardia Infections epidemiology, Pleuropneumonia drug therapy, Pleuropneumonia epidemiology, Retrospective Studies, Risk Factors, Skin Diseases, Bacterial drug therapy, Skin Diseases, Bacterial epidemiology, Soft Tissue Infections drug therapy, Soft Tissue Infections epidemiology, Tertiary Care Centers, Treatment Outcome, Trimethoprim, Sulfamethoxazole Drug Combination therapeutic use, Encephalitis diagnosis, Immunocompromised Host, Nocardia Infections diagnosis, Pleuropneumonia diagnosis, Skin Diseases, Bacterial diagnosis, Soft Tissue Infections diagnosis
- Abstract
Objectives: The objective of this study is to characterize the common risk factors, clinical presentation, imaging findings, treatment and outcome of nocardial infection., Design and Settings: A retrospective cohort study. We reviewed the charts of all patients with nocardiosis in the Chaim Sheba Medical Center, a tertiary medical center in Israel, between the years 1996 and 2011., Results: A total of 39 patients who had positive culture of Nocardia were analyzed. The majority of our patients were immunocompromised (74.5%), mostly due to corticosteroid therapy. None had HIV/AIDS. The clinical presentation was either acute or a chronic smoldering illness. The three major clinical syndromes were pleuropulmonary, neurological and skin/soft tissue infection about 20.5% each. Pathology in the lungs was seen in most of the patients by CT scan; discrete nodules and wedge shaped pleural based consolidations were the most frequent findings. Brain lesions consistent with abscesses were detected in 10 patients by brain imaging. Some cases had relapsing disease in spite of antimicrobial treatment. 25% of examined isolates were resistant to trimethoprim/sulfamethoxazole. The duration of intravenous antimicrobial treatment ranged from one month to over a year in the severe cases. One year mortality rate was 32%., Conclusion: Nocardiosis requires a high clinical index of suspicion in order to diagnose and treat promptly. Disease extent and bacterial susceptibility have important implications for prognosis and treatment., (Copyright © 2013 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
48. The tomato FT ortholog triggers systemic signals that regulate growth and flowering and substitute for diverse environmental stimuli.
- Author
-
Lifschitz E, Eviatar T, Rozman A, Shalit A, Goldshmidt A, Amsellem Z, Alvarez JP, and Eshed Y
- Subjects
- Cell Nucleus chemistry, Environment, Flowers anatomy & histology, Flowers genetics, Genes, Plant genetics, Solanum lycopersicum anatomy & histology, Solanum lycopersicum genetics, Meristem physiology, Mutation, Plant Leaves chemistry, Plant Leaves genetics, Plant Leaves metabolism, Plant Proteins analysis, Transcription, Genetic, Flowers growth & development, Gene Expression Regulation, Developmental, Gene Expression Regulation, Plant, Genes, Plant physiology, Solanum lycopersicum growth & development, Plant Proteins genetics
- Abstract
The systemic model for floral induction, dubbed florigen, was conceived in photoperiod-sensitive plants but implies, in its ultimate form, a graft-transmissible signal that, although activated by different stimuli in different flowering systems, is common to all plants. We show that SFT (SINGLE-FLOWER TRUSS), the tomato ortholog of FLOWERING LOCUS T (FT), induces flowering in day-neutral tomato and tobacco plants and is encoded by SFT. sft tomato mutant plants are late-flowering, with altered architecture and flower morphology. SFT-dependent graft-transmissible signals complement all developmental defects in sft plants and substitute for long-day stimuli in Arabidopsis, short-day stimuli in Maryland Mammoth tobacco, and light-dose requirements in tomato uniflora mutant plants. The absence of donor SFT RNA from flowering receptor shoots and the localization of the protein in leaf nuclei implicate florigen-like messages in tomato as a downstream pathway triggered by cell-autonomous SFT RNA transcripts. Flowering in tomato is synonymous with termination of the shoot apical meristems, and systemic SFT messages attenuate the growth of apical meristems before and independent of floral production. Floral enhancement by systemic SFT signals is therefore one pleiotropic effect of FT orthologs.
- Published
- 2006
- Full Text
- View/download PDF
49. Synthesis of insulin-like growth factor binding protein 3 in vitro in human articular cartilage cultures.
- Author
-
Eviatar T, Kauffman H, and Maroudas A
- Subjects
- Adult, Aged, Aged, 80 and over, Cells, Cultured, Humans, In Vitro Techniques, Insulin-Like Growth Factor Binding Protein 3 chemistry, Insulin-Like Growth Factor I biosynthesis, Insulin-Like Growth Factor I pharmacology, Middle Aged, Molecular Weight, Osteoarthritis metabolism, Osteoarthritis pathology, Cartilage, Articular cytology, Cartilage, Articular metabolism, Insulin-Like Growth Factor Binding Protein 3 biosynthesis
- Abstract
Objective: To quantify the rate of synthesis of insulin-like growth factor binding protein 3 (IGFBP-3) and insulin-like growth factor 1 (IGF-1) by in vitro cultures of normal and osteoarthritic (OA) human articular cartilage., Methods: Levels of IGF-1 and IGFBP-3 in media from in vitro cultures of human cartilage were determined by radioimmunoassay (RIA). IGFBPs were characterized by immunoblots and ligand blots. Ultrafiltration and RIA analysis of synovial fluid (SF) samples and washings of cartilage samples ex vivo were used to calculate partition coefficients and to estimate the amount of IGF-1 and IGFBP-3 in cartilage in vivo., Results: OA cartilage synthesized 150 ng of IGFBP-3 per gm of cartilage per day, compared with 50 ng synthesized by normal cartilage. The surface zone of normal cartilage produced more IGFBP-3 than did the deep zone. Immunoblots and ligand blots confirmed the presence of IGFBP-3. IGFBP-3 synthesis was stimulated by exogenous IGF-1. No freshly synthesized IGF-1 was detected. The quantities of IGF-1 and IGFBP-3 present ex vivo were 11.3 and 78.7 ng/gm of cartilage in normal cartilage and 21.6 and 225.4 ng/gm in OA cartilage., Conclusion: The results show that while IGFBP-3 is synthesized in explant cultures, IGF-1 is not. The rate of IGFBP-3 synthesis is 3 times higher in OA than in normal cartilage. Both IGFBP-3 and IGF-1 penetrate into cartilage from SF in vivo. We estimate that the quantities of IGFBP-3 produced in culture by human cartilage are small compared with the amount supplied in the form of "small complexes" from the circulation. The high value of the partition coefficient of IGFBP-3 implies binding to the matrix.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.